
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE is well-positioned for sustainable growth as it continues to scale and expand its market reach, with a strong pipeline of new products and a growing specialized sales force. With a solid financial performance in the first quarter, the company is on track to reach its goal of 100 territories within the next 12 months, and its partnership with SNN provides further opportunities for growth. The company's efficient operational practices and strong EBITDA outlook also bode well for its profitability and long-term success.
Bears say
SI-BONE is highly dependent on external factors such as regulations from governmental and private health-care providers, as well as partnerships with other medical companies like Smith & Nephew. The company's success is also tied to the adoption of their new DRG codes and reimbursement rates for their products, as shown in their projected $50,000 increase in hospital payments per procedure. However, their current valuation at 2x EV/Sales is a premium compared to their ortho & spine peers at 1.8x, and the sector has experienced multiple compression, leading to a decrease in their price target. Additionally, the definition of materiality in the ESG space can change over time, making it difficult to accurately evaluate a company's performance in this area.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares